Nghiên cứu đa trung tâm giai đoạn I/II về hóa trị liệu khởi đầu với docetaxel, cisplatin và fluorouracil (DCF) theo sau là hóa xạ trị ở bệnh nhân bị ung thư thực quản cục bộ tiến xa không thể phẫu thuật

Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D (1994) An audit of the treatment of cancer of the oesophagus. Gut 35(7):941–945 Ikeda K, Ishida K, Sato N, Koeda K, Aoki K, Kimura Y, Iwaya T, Ogasawara S, Iijima S, Nakamura R, Uesugi N, Maesawa C, Saito K (2001) Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus 14(3–4):197–201 Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34(10):615–619. doi:10.1093/jjco/hyh107 Matsubara T, Ueda M, Kokudo N, Takahashi T, Muto T, Yanagisawa A (2001) Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg 25(3):279–284. doi:10.1007/s002680020060 Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25(10):1160–1168. doi:10.1200/JCO.2005.04.7118 Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326(24):1593–1598. doi:10.1056/NEJM199206113262403 Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281(17):1623–1627 Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17(9):2915–2921 Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, Kosugi S, Toh Y, Nakamura K, Fukuda H, Japan Clinical Oncology G (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106(4):407–412. doi:10.1111/cas.12622 Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le BN, Clavel M, Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5(6):533–537 Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14(5):1672–1678 Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715. doi:10.1056/NEJMoa070956 Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704. doi:10.1056/NEJMoa071028 Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455–1460. doi:10.1111/cas.12274 Chiarion-Sileni V, Corti L, Ruol A, Innocente R, Boso C, Del Bianco P, Pigozzo J, Mazzarotto R, Tomassi O, Ancona E (2007) Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 96(3):432–438. doi:10.1038/sj.bjc.6603585 Japanese classification of esophageal cancer, 10th ed (2008). Parts II and III. Esophagus 6(2):71–94 Nakamura T, Hayashi K, Ota M, Eguchi R, Ide H, Takasaki K, Mitsuhashi N (2004) Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg 188(3):261–266. doi:10.1016/j.amjsurg.2004.06.003 Tomimaru Y, Yano M, Takachi K, Miyashiro I, Ishihara R, Nishiyama K, Sasaki Y, Ishikawa O, Doki Y, Imaoka S (2006) Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 93(5):422–428. doi:10.1002/jso.20475 Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL (2002) Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123(1):175–183 Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, Ishikura S, Ohtsu A, Yoshida S (2008) Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 40(9):717–721. doi:10.1055/s-2008-1077480 Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272. doi:10.1007/s00280-010-1422-x Muro K (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959. doi:10.1093/annonc/mdh231 Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W, Kitasato Digestive D, Oncology G (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase II trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89(4):872–879. doi:10.1016/j.ijrobp.2014.03.030 Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174 Ohtsu A, Yoshida S, Boku N, Fujii T, Miyata Y, Hosokawa K, Koba I, Shimizu W, Ogino T (1995) Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 25(6):261–266